发布求助
文献互助 智能选刊 最新文献

Future cardiology最新文献

筛选
英文 中文
Outcomes of graft angiography with distal radial access: a retrospective cohort study. 使用桡动脉远端入路进行移植血管造影的结果：一项回顾性队列研究。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-15 DOI: 10.1080/14796678.2024.2373592
Hamid Iqbal, Fnu Manoj Kumar, Farrukh Mehmood, Fnu Kiran, Kajal Bai, Kajal Kumari, Fnu Suman, Deepak Kumar, Deepa Rani, Saroop Kumar Alies Rahol Rai, Jahanzeb Malik, Waheed Akhtar
{"title":"Outcomes of graft angiography with distal radial access: a retrospective cohort study.","authors":"Hamid Iqbal, Fnu Manoj Kumar, Farrukh Mehmood, Fnu Kiran, Kajal Bai, Kajal Kumari, Fnu Suman, Deepak Kumar, Deepa Rani, Saroop Kumar Alies Rahol Rai, Jahanzeb Malik, Waheed Akhtar","doi":"10.1080/14796678.2024.2373592","DOIUrl":"10.1080/14796678.2024.2373592","url":null,"abstract":"<p><p><b>Background:</b> This retrospective cohort study aimed to compare the outcomes of graft angiography using these two approaches.<b>Methods:</b> Medical records and angiographic data of adult patients who underwent graft angiography between January 2020 and December 2022 were analyzed.<b>Results:</b> The study included 452 patients in the distal radial access (DRA) group and 960 patients in the femoral access group. Angiographic characteristics showed a higher prevalence of triple vessel disease in the femoral access group (29.8% vs. 20.8%; <i>p</i> = 0.012). The DRA group had a procedural success rate of 93.0%, while the femoral access group had a higher success rate of 95.8%. The odds ratio was 0.66 (95% CI: 0.46-0.94), indicating lower odds of procedural success in the DRA group.<b>Conclusion:</b> Our study suggests that both DRA and femoral access are effective and safe approaches for graft angiography after coronary artery bypass surgery.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"479-484"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists. 耐药性高血压治疗的最新进展：聚焦内皮素受体拮抗剂。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI: 10.1080/14796678.2024.2367390
Sayeh Heidari Nejad, Omar Azzam, Markus P Schlaich
{"title":"Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.","authors":"Sayeh Heidari Nejad, Omar Azzam, Markus P Schlaich","doi":"10.1080/14796678.2024.2367390","DOIUrl":"10.1080/14796678.2024.2367390","url":null,"abstract":"<p><p>Resistant hypertension is characterized by the inability of guideline-recommended triple combination therapy to control blood pressure (BP) to target. It is associated with a significantly increased risk of adverse outcomes. Despite abundant preclinical evidence supporting the critical role of the endothelin pathway in resistant hypertension (RH), clinical implementation of endothelin antagonists for the treatment of hypertension was hindered by various factors. Recently, the novel dual endothelin-receptor antagonist aprocitentan was tested in individuals with resistant hypertension in the PRECISION trial and provided compelling evidence supporting both short and longer-term safety and clinically meaningful and sustained BP lowering efficacy. These findings resulted in the recent regulatory approval of aprocitentan by the FDA. Aprocitentan may be a particularly useful antihypertensive option for individuals with advanced age, chronic kidney disease, and albuminuria.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"435-445"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients. SGLT2 抑制剂对蒽环类药物引起的心脏毒性的疗效：一项针对癌症患者的荟萃分析。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-04 DOI: 10.1080/14796678.2024.2363673
Sana Mohsin, Misha Hasan, Zubaid Moazzam Sheikh, Fatima Mustafa, Vesna Tegeltija, Sarwan Kumar, Jai Kumar
{"title":"Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients.","authors":"Sana Mohsin, Misha Hasan, Zubaid Moazzam Sheikh, Fatima Mustafa, Vesna Tegeltija, Sarwan Kumar, Jai Kumar","doi":"10.1080/14796678.2024.2363673","DOIUrl":"10.1080/14796678.2024.2363673","url":null,"abstract":"<p><p><b>Aim:</b> Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity.<b>Methods:</b> PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI).<b>Results:</b> 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); <i>p</i> = 0.005; I<sup>2</sup>= 32%], HF hospitalization [RR = 0.20 (0.04-1.02); <i>p</i> = 0.05; I<sup>2</sup>= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); <i>p</i> = 0.11, I<sup>2</sup>= 0%].<b>Conclusion:</b> SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"395-407"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia. 鼻内注射依曲帕米快速治疗阵发性室上性心动过速。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-05-20 DOI: 10.1080/14796678.2024.2342651
Peter Calvert, Dhiraj Gupta
{"title":"Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia.","authors":"Peter Calvert, Dhiraj Gupta","doi":"10.1080/14796678.2024.2342651","DOIUrl":"10.1080/14796678.2024.2342651","url":null,"abstract":"<p><p>Paroxysmal supraventricular tachycardia (PSVT) is a common arrhythmia that, although usually benign, can occur unpredictably, cause disabling symptoms and significantly impair quality of life. If spontaneous resolution does not occur, the only current self-treatment is for the patient to attempt vagal maneuvers, however, these are frequently unsuccessful. Hospital attendance is then required for intravenous therapy. Etripamil, an intranasal calcium channel blocker similar to verapamil, may be able to fill this therapeutic gap, allowing rapid self-treatment of PSVT at home. This narrative review discusses the latest evidence for etripamil and its potential role in future clinical practice.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"163-170"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polymer-free stents for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis. 用于糖尿病患者经皮冠状动脉介入治疗的不含聚合物的支架：系统综述和荟萃分析。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1080/14796678.2024.2370688
Filippo Luca Gurgoglione, Davide Donelli, Michele Antonelli, Luigi Vignali, Giorgio Benatti, Emilia Solinas, Iacopo Tadonio, Giulia Magnani, Andrea Denegri, Davide Lazzeroni, Rocco Antonio Montone, Riccardo C Bonadonna, Francesco Nicolini, Diego Ardissino, Giampaolo Niccoli
{"title":"Polymer-free stents for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis.","authors":"Filippo Luca Gurgoglione, Davide Donelli, Michele Antonelli, Luigi Vignali, Giorgio Benatti, Emilia Solinas, Iacopo Tadonio, Giulia Magnani, Andrea Denegri, Davide Lazzeroni, Rocco Antonio Montone, Riccardo C Bonadonna, Francesco Nicolini, Diego Ardissino, Giampaolo Niccoli","doi":"10.1080/14796678.2024.2370688","DOIUrl":"10.1080/14796678.2024.2370688","url":null,"abstract":"<p><p><b>Aim:</b> To compare the efficacy of polymer-free drug-eluting stents (PF-DES) versus other stents in diabetic patients with coronary artery disease undergoing percutaneous coronary interventions.<b>Materials & methods:</b> A systematic review and meta-analysis were performed to identify pertinent randomized controlled trials. The primary end point was the occurrence of target lesion failure.<b>Results:</b> Eight randomized controlled trials were included for a total of 4854 subjects. The PF-DES group experienced a trend in favor of a lower rate of target lesion failure (Incidence rate ratio = 0.91; <i>p</i> = 0.11) and a significantly lower rate of cardiac mortality, as compared with the control group (Incidence rate ratio = 0.82; <i>p</i> = 0.04). However, statistical significance was lost if bare-metal stent patients were excluded and a trend in favor of the PF-DES strategy was reported only for cardiac mortality.<b>Conclusion:</b> PF-DES could be a valuable strategy in diabetic patients with coronary artery disease undergoing percutaneous coronary interventions.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"485-497"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology. "一刀切 "真的适合所有人吗？介入心脏病学中个性化抗血小板治疗的案例。
IF 1.6
Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-08-02 DOI: 10.1080/14796678.2024.2384217
Ahmed Elserwey, Richard J Jabbour, Nick Curzen
{"title":"Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.","authors":"Ahmed Elserwey, Richard J Jabbour, Nick Curzen","doi":"10.1080/14796678.2024.2384217","DOIUrl":"10.1080/14796678.2024.2384217","url":null,"abstract":"<p><p>Cardiovascular disease is the leading cause of death worldwide. Dual antiplatelet therapy (DAPT), with aspirin plus a P2Y12 inhibitor, is currently recommended as a default for patients after acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). However, controversies arise over the role of aspirin, the optimal duration of DAPT after drug-eluting stent (DES) implantation, the choice of P2Y12 inhibitor and the variability in individual responses to antiplatelet agents. Recent data indicate that monotherapy with a P2Y12 inhibitor may have adequate anti-ischemic effects with lower bleeding risk. Additionally, discrepancies in DAPT duration recommendations and the optimal P2Y12 inhibitor, provides more uncertainty. We ask the question \"does one size really fits all?\" or should a more personalized strategy should be implemented.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"499-515"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiology in the digital era: from artificial intelligence to Metaverse, paving the way for future advancements. 数字时代的心脏病学：从人工智能到元宇宙，为未来进步铺平道路。
IF 1.7
Future cardiology Pub Date : 2023-12-01 Epub Date: 2024-01-08 DOI: 10.2217/fca-2023-0106
Ioannis Skalidis, Ioannis Kachrimanidis, Leonidas Koliastasis, Dimitri Arangalage, Panagiotis Antiochos, Niccolo Maurizi, Olivier Muller, Stephane Fournier, Michalis Hamilos, Emmanouil Skalidis
{"title":"Cardiology in the digital era: from artificial intelligence to Metaverse, paving the way for future advancements.","authors":"Ioannis Skalidis, Ioannis Kachrimanidis, Leonidas Koliastasis, Dimitri Arangalage, Panagiotis Antiochos, Niccolo Maurizi, Olivier Muller, Stephane Fournier, Michalis Hamilos, Emmanouil Skalidis","doi":"10.2217/fca-2023-0106","DOIUrl":"10.2217/fca-2023-0106","url":null,"abstract":"<p><p>Tweetable abstract Cardiology's digital revolution: AI diagnoses, ChatGPT consults, Metaverse educates. Challenges & promises explored. #CardiologyTech #DigitalHealth.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"755-758"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139377455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dressler syndrome in the 21st Century. 21世纪的德雷斯勒综合征。
IF 1.7
Future cardiology Pub Date : 2023-12-01 Epub Date: 2023-11-07 DOI: 10.2217/fca-2023-0100
Matthew Cotton, Frederick Sweeting
{"title":"Dressler syndrome in the 21<sup>st</sup> Century.","authors":"Matthew Cotton, Frederick Sweeting","doi":"10.2217/fca-2023-0100","DOIUrl":"10.2217/fca-2023-0100","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"719-721"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Massive anterior mediastinal lipoma causing cardiac arrest in a middle-aged male: a case report and literature review. 导致一名中年男性心脏骤停的巨大前纵隔脂肪瘤：病例报告和文献综述。
IF 1.7
Future cardiology Pub Date : 2023-12-01 Epub Date: 2023-12-19 DOI: 10.2217/fca-2023-0107
Xulin Weng, Le Jiang, Menglu Zhou
{"title":"Massive anterior mediastinal lipoma causing cardiac arrest in a middle-aged male: a case report and literature review.","authors":"Xulin Weng, Le Jiang, Menglu Zhou","doi":"10.2217/fca-2023-0107","DOIUrl":"10.2217/fca-2023-0107","url":null,"abstract":"<p><p>Lipoma is a common benign soft tissue tumor, but its size and location can lead to serious issues. We report a case of a 48 year-old male patient who experienced sudden cardiac arrest outside the hospital. After resuscitation and examination, we determined that this was due to a massive mediastinal lipoma compressing the lungs, leading to respiratory failure and pulmonary encephalopathy, ultimately resulting in cardiac arrest. This case serves as a reminder to promptly identify and manage chest lipomas to avoid compression and functional impairment of the respiratory system. Early evaluation and treatment of massive lipomas are crucial for preventing complications.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"747-752"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lower myocardial infarction and all-cause mortality with laparoscopic cholecystectomy compared with open cholecystectomy. 腹腔镜胆囊切除术与开腹胆囊切除术相比，心肌梗死和全因死亡率更低。
IF 1.7
Future cardiology Pub Date : 2023-12-01 Epub Date: 2023-12-19 DOI: 10.2217/fca-2023-0102
Taft Keele, Mehrtash Hashemzadeh, Mohammad Reza Movahed
{"title":"Lower myocardial infarction and all-cause mortality with laparoscopic cholecystectomy compared with open cholecystectomy.","authors":"Taft Keele, Mehrtash Hashemzadeh, Mohammad Reza Movahed","doi":"10.2217/fca-2023-0102","DOIUrl":"10.2217/fca-2023-0102","url":null,"abstract":"<p><p><b>Aim:</b> We compared inpatient outcome data of open (OC) versus laparoscopic cholecystectomy (LC). <b>Patients & methods:</b> We used the National Inpatient Samples database from 2010-2014. <b>Results:</b> LC was done in 340,999 and OC in 68,529 OC patients. In 2010, ST-elevation myocardial infarction (STEMI) prevalence was 0.2 versus 0% (OR: 3.1, CI: 1.7-5.5; p < 0.001), non-STEMI 1 versus 0.4% (OR: 2.5 CI: 2.0-3.0; p < 0001), mortality 3.4 versus 0.4% (OR: 9.2, CI: 7.9-10.6; p < 0001). After multivariate adjustment, OC remained independently associated with STEMI, non-STEMI and all-cause inpatient mortality (mortality multivariate OR: 6.4, CI: 5.5-7.4; p < 0001, STEMI OR: 2.2. CI: 1.2-3.9; p = 0.007, non-STEMI OR: 1.5, CI: 1.3-1.9; p < 0001). <b>Conclusion:</b> OC is independently associated with STEMI, non-STEMI and all-cause inpatient mortality compared with LC.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"759-765"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信